Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis (AZIVAL2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01903057|
Recruitment Status : Withdrawn (As of November 2013, the security situation in rural Northern Mozambique is no longer suitable for this clinical trial.)
First Posted : July 19, 2013
Last Update Posted : May 22, 2014
Information provided by (Responsible Party):
Huub Gelderblom MD, PhD, MPH, Emory University
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Recruitment Status :||Withdrawn|
|Estimated Primary Completion Date :||March 2014|
|Estimated Study Completion Date :||July 2014|
Coulibaly YI, Dicko I, Keita M, Keita MM, Doumbia M, Daou A, Haidara FC, Sankare MH, Horton J, Whately-Smith C, Sow SO. A cluster randomized study of the safety of integrated treatment of trachoma and lymphatic filariasis in children and adults in Sikasso, Mali. PLoS Negl Trop Dis. 2013 May 9;7(5):e2221. doi: 10.1371/journal.pntd.0002221. Print 2013.